Sharemarket darling Telix Pharmaceuticals is set to earn its first sales revenues for its prostate cancer imaging product Illucix in early 2022 after the US healthcare regulator approved its use on Monday.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
